Trexquant Investment LP Sells 29,975 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

Trexquant Investment LP trimmed its position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 57.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,864 shares of the company's stock after selling 29,975 shares during the period. Trexquant Investment LP's holdings in Vera Therapeutics were worth $925,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Geode Capital Management LLC grew its position in Vera Therapeutics by 14.8% in the 4th quarter. Geode Capital Management LLC now owns 1,153,325 shares of the company's stock worth $48,787,000 after purchasing an additional 148,660 shares in the last quarter. Alliancebernstein L.P. increased its position in shares of Vera Therapeutics by 2.0% during the fourth quarter. Alliancebernstein L.P. now owns 40,350 shares of the company's stock valued at $1,706,000 after acquiring an additional 800 shares during the last quarter. Schroder Investment Management Group lifted its holdings in Vera Therapeutics by 1.8% during the fourth quarter. Schroder Investment Management Group now owns 485,145 shares of the company's stock worth $20,405,000 after acquiring an additional 8,432 shares during the period. Pictet Asset Management Holding SA boosted its position in Vera Therapeutics by 47.1% in the fourth quarter. Pictet Asset Management Holding SA now owns 841,313 shares of the company's stock worth $35,579,000 after purchasing an additional 269,315 shares during the last quarter. Finally, Norges Bank bought a new position in Vera Therapeutics in the 4th quarter valued at $2,055,000. Institutional investors own 99.21% of the company's stock.

Vera Therapeutics Price Performance

Shares of VERA stock traded down $0.60 during trading hours on Wednesday, hitting $20.99. 91,514 shares of the company's stock were exchanged, compared to its average volume of 752,697. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. Vera Therapeutics, Inc. has a 12-month low of $18.53 and a 12-month high of $51.61. The business's 50 day simple moving average is $26.94 and its 200-day simple moving average is $36.95. The company has a market capitalization of $1.34 billion, a PE ratio of -8.05 and a beta of 1.28.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.11. On average, equities research analysts anticipate that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Analyst Ratings Changes

VERA has been the subject of a number of research reports. Guggenheim increased their target price on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. Wolfe Research assumed coverage on shares of Vera Therapeutics in a report on Tuesday, February 4th. They set an "outperform" rating and a $49.00 price objective on the stock. JPMorgan Chase & Co. reduced their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a research note on Tuesday, March 4th. Finally, The Goldman Sachs Group assumed coverage on Vera Therapeutics in a report on Tuesday, January 28th. They set a "buy" rating and a $58.00 price objective on the stock. One research analyst has rated the stock with a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, Vera Therapeutics has a consensus rating of "Buy" and an average target price of $64.67.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.